cit | Article | July/August 2017
cit | Article | July/August 2018
cit | Article | January/February 2013
cit | News | December 11, 2012
BELLO Supports Use of Medtronic's In.Pact Falcon DEB in Treating Small Vessels
December 11, 2012—Results from the BELLO (Balloon Elution and Late Loss Optimization) study, which aims to evaluate the efficacy of drug-eluting balloons (DEB) compared with paclitaxel-eluting stents (PES) for the reduction of restenosis in small vessels, were published by Azeem Latib, MD, et al in the Journal of the American College of Cardiology (2012;60:2473–2480).
cit | News | June 11, 2019
Transseptal Solutions Announces First Clinical Use of TSP Crosser in the United States
June 12, 2019—Transseptal Solutions Ltd., an Israel-based developer of the TSP Crosser, which provides transseptal puncture and left atrial navigation in a single device, announced that the first transseptal puncture procedure in the United States was successfully performed by Azeem Latib, MD, in a patient undergoing percutaneous balloon mitral valvuloplasty.
cit | News | March 14, 2013
Six-Month DISCOVER Outcomes Support Direct Flow Medical's TAVR System
March 12, 2013—Direct Flow Medical, Inc. (Santa Rosa, CA) announced that the DISCOVER trial results showed that a cohort of 33 patients treated with the Direct Flow Medical transcatheter aortic valve system achieved excellent survivability and sustained hemodynamic improvements with minimal occurrence of aortic regurgitation at 6 months.
cit | News | February 3, 2020
Expansion of Ancora Heart’s CorCinch HFrEF Early Feasibility Study Approved by FDA
February 3, 2020—Ancora Heart, Inc. announced that the FDA has approved an expansion of enrollment in the company's early feasibility study (EFS) evaluating the AccuCinch ventricular repair system in patients with reduced ejection fraction heart failure (HFrEF).
cit | News | September 26, 2016
4Tech's Transcatheter Tricuspid Valve Repair System Used Without TEE or General Anesthesia in Feasibility Study
September 27, 2016—4Tech Inc., which is developing the TriCinch transcatheter device for tricuspid heart valve repair, recently announced that the device has been used in the first-ever successful transcatheter tricuspid valve repair without the use of transesophageal echocardiography (TEE) or general anesthesia to successfully treat a patient with tricuspid regurgitation (TR).
cit | News | March 15, 2017
Innovative Cardiovascular Solutions Begins European Study of the Emblok Embolic Protection System
March 15, 2017—Innovative Cardiovascular Solutions (ICS) announced the successful first European clinical cases using the company's Emblok embolic protection system in patients undergoing transcatheter aortic valve replacement (TAVR) procedures.
cit | News | June 5, 2020
CE Mark Approved for 1-Month DAPT Indication for High Bleeding Risk Patients Treated With Medtronic’s Resolute Onyx DES
June 5, 2020—Medtronic announced it has received European CE Mark approval for a 1-month dual antiplatelet therapy (DAPT) indication for high bleeding risk (HBR) patients implanted with the Resolute Onyx drug-eluting stent (DES).
cit | News | February 20, 2020
FDA Approves Early Feasibility Study and Grants Breakthrough Device Designation for Cardiovalve System
February 20, 2020—Cardiovalve announced that it has received FDA approval for an early feasibility study (EFS) of its transcatheter tricuspid valve replacement system for a tricuspid regurgitation (TR) indication.